Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. insiders are currently net buyers of SYRS stock, showing bullish sentiment over the past 90 days. Executives have purchased $52.2M while selling $8.7M, resulting in a positive net flow of $43.4M. This buying activity represents 86% of total transaction volume.

Syros Pharmaceuticals, Inc. has 35 active insiders who have filed SEC Form 4 transactions in the past 90 days. Srinivas Akkaraju (Executive) leads with 21 transactions totaling $14.8M. Jeremy Green (Executive) follows with 9 transactions worth $5.4M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Syros Pharmaceuticals, Inc.'s current score of 86/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $52.2M in purchases versus $8.7M in sales.

The most recent insider transaction occurred on Oct 31, 2024, when Stephens Kristin (Executive) disposed of 17,000 shares at $0.00 per share for $0. This was executed under a 10b5-1 trading plan.

Based on SEC Form 4 filings from the past 90 days, SYRS insider trading sentiment is currently bullish with an Alignment Score of 86/100. The net insider flow of $43.4M reflects accumulation, with 86% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Syros Pharmaceuticals, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At SYRS, we track all Form 4 filings—currently showing 251 transactions from 35 insiders over 90 days.

A 10b5-1 plan allows Syros Pharmaceuticals, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At SYRS, approximately 18% of recent transactions are 10b5-1 trades. The remaining 82% are discretionary trades, which may carry more informational value.

You can monitor Syros Pharmaceuticals, Inc. (SYRS) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 35 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Syros Pharmaceuticals, Inc.'s current score of 86/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $52.2M in purchases versus $8.7M in sales over 90 days, resulting in a net flow of $43.4M.

SEC Form 4 filings are mandatory reports that Syros Pharmaceuticals, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At SYRS, the most common type is "M" with 20 occurrences. The most recent Form 4 was filed on Oct 31, 2024 by Stephens Kristin.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Syros Pharmaceuticals, Inc., approximately 18% of recent transactions are executed under 10b5-1 plans, while 82% appear to be discretionary trades. The low percentage means most insider activity at SYRS represents discretionary decisions with more informational value.